Frederick Ling, MD
Interventional Cardiology · Rochester, NYNPI 1508808304
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $37,550 of the $48,955 with a category attached, or 76.7%. Edwards Lifesciences accounts for 86.2% of it on its own, with 6 other manufacturers making up the rest.
Across 111 payments — averaging $441.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$42K
- Magenta Medical Inc$3K
- Medtronic$2K
- Abbott$2K
- Boston Scientific$293
- CSL Behring$23
- plus $12 from 1 others
Across 94 payments — averaging $2479.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$164K
- CSL Behring$45K
- Abbott$24K
What the payments were for
- Consulting fees$37,55077%
- Travel & lodging$9,12019%
- Food & beverage$2,2855%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 86 | $42,185 |
| Magenta Medical Inc | 2 | $3,300 |
| Medtronic | 6 | $1,577 |
| Abbott | 13 | $1,565 |
| Boston Scientific | 2 | $293 |
| CSL Behring | 1 | $23 |
| Vapotherm Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,955 in reported general payments places this provider in the 80th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 33 | $52,117 |
| Repatha SureclickEvolocumab | 38 | $28,528 |
| EntrestoSacubitril/Valsartan | 17 | $20,456 |
| JardianceEmpagliflozin | 15 | $17,031 |
| Ranolazine ErRanolazine | 11 | $1,270 |
| Atorvastatin Calcium | 63 | $1,014 |
| Metoprolol Succinate | 44 | $926 |
| ClopidogrelClopidogrel Bisulfate | 45 | $685 |
| Valsartan | 11 | $469 |
| Carvedilol | 29 | $450 |
| Rosuvastatin Calcium | 13 | $429 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 24 | $340 |
| Torsemide | 17 | $333 |
| Ezetimibe | 20 | $194 |
| Amlodipine Besylate | 23 | $163 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Rochester
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- David CohenRoslyn$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.